Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.

Neoh CF, Liew D, Slavin M, Marriott D, Chen SC, Morrissey O, Stewart K, Kong DC.

J Antimicrob Chemother. 2011 Aug;66(8):1906-15. doi: 10.1093/jac/dkr186. Erratum in: J Antimicrob Chemother. 2012 Apr;67(4):1052.

PMID:
21628305
2.

Candidemia in the intensive care unit: miles to go before we sleep.

Pappas PG; Mycoses Study Group..

Crit Care Med. 2011 Apr;39(4):884-5. doi: 10.1097/CCM.0b013e31820f710b. No abstract available.

PMID:
21613835
3.

Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.

Pfaller MA, Andes D, Arendrup MC, Diekema DJ, Espinel-Ingroff A, Alexander BD, Brown SD, Chaturvedi V, Fowler CL, Ghannoum MA, Johnson EM, Knapp CC, Motyl MR, Ostrosky-Zeichner L, Walsh TJ.

Diagn Microbiol Infect Dis. 2011 Jul;70(3):330-43. doi: 10.1016/j.diagmicrobio.2011.03.002. Review.

PMID:
21546199
4.
5.

Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS; CLSI Subcommittee for Antifungal Testing..

Drug Resist Updat. 2011 Jun;14(3):164-76. doi: 10.1016/j.drup.2011.01.004. Review.

PMID:
21353623
6.

Antifungal use in hospitalized adults in U.S. academic health centers.

Pakyz AL, Gurgle HE, Oinonen MJ.

Am J Health Syst Pharm. 2011 Mar 1;68(5):415-8. doi: 10.2146/ajhp100423.

PMID:
21330683
7.

FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.

Costa-de-Oliveira S, Marcos Miranda I, Silva RM, Pinto E Silva A, Rocha R, Amorim A, Gonçalves Rodrigues A, Pina-Vaz C.

Antimicrob Agents Chemother. 2011 Mar;55(3):1312-4. doi: 10.1128/AAC.00589-10.

8.

Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin.

Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D.

J Clin Microbiol. 2011 Feb;49(2):624-9. doi: 10.1128/JCM.02120-10.

9.

Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei.

Shorr AF, Wu C, Kothari S.

J Antimicrob Chemother. 2011 Feb;66(2):375-80. doi: 10.1093/jac/dkq446.

PMID:
21147825
10.

Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.

Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F; French Mycosis Study Group..

Antimicrob Agents Chemother. 2011 Feb;55(2):532-8. doi: 10.1128/AAC.01128-10.

12.

Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.

Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D; CLSI Subcommittee for Antifungal Susceptibility Testing..

Drug Resist Updat. 2010 Dec;13(6):180-95. doi: 10.1016/j.drup.2010.09.002. Review.

PMID:
21050800
13.

National surveillance of fungemia in Denmark (2004 to 2009).

Arendrup MC, Bruun B, Christensen JJ, Fuursted K, Johansen HK, Kjaeldgaard P, Knudsen JD, Kristensen L, Møller J, Nielsen L, Rosenvinge FS, Røder B, Schønheyder HC, Thomsen MK, Truberg K.

J Clin Microbiol. 2011 Jan;49(1):325-34. doi: 10.1128/JCM.01811-10.

14.

FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.

Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, Lockhart SR.

Antimicrob Agents Chemother. 2010 Dec;54(12):5042-7. doi: 10.1128/AAC.00836-10.

15.

A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients.

Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A.

J Antimicrob Chemother. 2010 Aug;65(8):1765-70. doi: 10.1093/jac/dkq216.

PMID:
20554567
16.

Clinical and economic outcomes of decreased fluconazole susceptibility in patients with Candida glabrata bloodstream infections.

Lee I, Morales KH, Zaoutis TE, Fishman NO, Nachamkin I, Lautenbach E.

Am J Infect Control. 2010 Nov;38(9):740-5. doi: 10.1016/j.ajic.2010.02.016.

17.

Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?

Oxman DA, Chow JK, Frendl G, Hadley S, Hershkovitz S, Ireland P, McDermott LA, Tsai K, Marty FM, Kontoyiannis DP, Golan Y.

J Antimicrob Chemother. 2010 Jul;65(7):1460-5. doi: 10.1093/jac/dkq136.

PMID:
20430790
18.

Breakthrough invasive candidiasis in patients on micafungin.

Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD.

J Clin Microbiol. 2010 Jul;48(7):2373-80. doi: 10.1128/JCM.02390-09.

19.
20.

Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.

Castanheira M, Woosley LN, Diekema DJ, Messer SA, Jones RN, Pfaller MA.

Antimicrob Agents Chemother. 2010 Jun;54(6):2655-9. doi: 10.1128/AAC.01711-09.

Supplemental Content

Support Center